Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats

ACS Chemical Neuroscience

Volumn 4, Issue 5, 2013, Pages 747-760

  Dupre, Kristin B ^a   Ostock, Corinne Y ^a   George, Jessica A ^a   Eskow Jaunarajs, Karen L ^a   Hueston, Cara M ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

5 HT1A receptor; D1 receptor; Dyskinesia; GABA; Glutamate; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINOBUTYRIC ACID; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; MESSENGER RNA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; BENZAZEPINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DYNORPHIN; N (2 (4 (2 METHOXYPHENYL) 1 PIPERAZINYL)ETHYL) N (2 PYRIDINYL)CYCLOHEXANECARBOXAMIDE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PRE PRODYNORPHIN; PRE-PRODYNORPHIN; PROTEIN PRECURSOR; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; SK&F 81297;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; IN VIVO STUDY; INVOLUNTARY MOVEMENT; MALE; MICRODIALYSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANIMAL BEHAVIOR; DRUG POTENTIATION; METABOLISM; MOTOR ACTIVITY; NEOSTRIATUM; SUBSTANTIA NIGRA;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; DOPAMINE AGONISTS; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; GLUTAMATE DECARBOXYLASE; MOTOR ACTIVITY; NEOSTRIATUM; PARKINSONIAN DISORDERS; PIPERAZINES; PROTEIN PRECURSORS; PYRIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D1; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SUBSTANTIA NIGRA;

EID: 84877815091     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300234z     Document Type: Article

References (73)

1. Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130, 1819-1833
2. 1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy Pharmacol., Biochem. Behav. 87, 306-314
3. Eskow, K. L., Dupre, K. B., Barnum, C. J., Dickinson, S. O., Park, J. Y., and Bishop, C. (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-DOPA-induced dyskinesia in hemiparkinsonian rats Synapse 63, 610-620
4. 1A receptor stimulation Neuropharmacology 61, 753-760
5. Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T., Nutt, J., and Rascol, O. 2004, Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) Clin. Neuropharmacol. 27, 58-62
6. Bara-Jimenez, W., Bibbiani, F., Morris, M. J., Dimitrova, T., Sherzai, A., and Mouradian, M. M. 2005, Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease Mov. Disord. 20, 932-936
7. 1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats J. Neurosci. Res. 87, 1645-1658
8. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions Brain Res. 1112, 126-133
9. 1A) receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: Implications for Parkinson's disease Psychopharmacology (Berlin, Ger.) 192, 49-59
10. 1A agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability J. Pharmacol. Exp. Ther. 319, 1225-1234
11. Carey, R. J., DePalma, G., Damianopoulos, E., Muller, C. P., and Huston, J. P. (2004) The 5-HT1A receptor and behavioral stimulation in the rat: Effects of 8-OHDPAT on spontaneous and cocaine-induced behavior Psychopharmacology 177, 46-54
12. Goetz, C. G., Damier, P., Hicking, C., Laska, E., Muller, T., Olanow, C. W., Rascol, O., and Russ, H. (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov. Disord. 22, 179-186
13. Carta, M., Lindgren, H., Lundblad, M., Stancampiano, R., Fadda, F., and Cenci, M. A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats J. Neurochem. 96, 1718-1727
14. Cenci, M. A., Ohlin, K. E., and Rylander, D. (2009) Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia Parkinsonism Relat. Disord. 15, S59-93
15. Kannari, K., Yamato, H., Shen, H., Tomiyama, M., Suda, T., and Matsunaga, M. (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-dopa in the striatum with nigrostriatal denervation J. Neurochem. 76, 1346-1353
16. Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., and Cenci, M. A. (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 (6) 1465-1476
17. Sgambato-Faure, V. and Cenci, M. A. (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease Prog. Neurobiol. 96, 69-86
18. Robelet, S., Melon, C., Guillet, B., Salin, P., and Kerkerian-LeGoff, L. (2004) Chronic l-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease Eur. J. Neurosci. 20, 1255-1266
19. Samadi, P., Gregoire, L., Morissette, M., Calon, F., Tahar, A. H., and Dridi, M. 2008, mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys Neurobiol. Aging 29, 1040-1051
20. 1A receptor stimulation in dyskinetic, hemiparkinsonian rats Exp. Neurol. 229, 288-299
21. Calon, F., Rajput, A. H., Hornykiewicz, O., Bedard, P. J., and Di Paolo, T. (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 (3) 404-416
22. Ouattara, B., Gregoire, L., Morissette, M., Gasparini, F., Vranesic, I., Bilbe, G., Johns, D. R., Rajput, A., Hornykiewicz, O., Rajput, A. H., Gomez-Mancilla, B., and Di Paolo, T. (2011) Metabotropic glutamate receptor type 5 in levodopa-induced motor complications Neurobiol. Aging 32 (7) 1286-1295
23. Johnson, K. A., Conn, P. J., and Niswender, C. M. (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord. Drug Targets 8 (6) 475-491
24. Cenci, M. A. (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia Trends Neurosci. 30, 236-243
25. Westin, J. E., Vercammen, L., Strome, E. M., Konradi, C., and Cenci, M. A. (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors Biol. Psychiatry 62, 800-810
26. Gerfen, C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia Annu. Rev. Neurosci. 15, 285-320
27. Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., and Adler, E. M. 1992, Molecular cloning of the rat A2 adenosine receptor: selective coexpression with D2 dopamine receptor in rat striatum Mol. Brain Res. 14, 186-95
28. Cenci, M. A., Lee, C. S., and Bjorklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10, 2694-2706
29. Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., and Cenci, M. A. (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease J. Neurochem. 101, 483-497
30. Wang, H., Katz, J., Dagostino, P., and Soghomonian, J. J. (2007) Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata Neurosci. 145, 727-37
31. Laprade, N. and Soghomonian, J. J. (1999) Gene expression of the GAD67 and GAD65 isoforms of glutamate decarboxylase is differentially altered in subpopulations of striatal neurons in adult rats lesioned with 6-OHDA as neonates Synapse 33, 36-48
32. 1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease Neurosci. Res. 52, 185-194
33. Mela, F., Marti, M., Bido, S., Cenci, M. A., and Morari, M. (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels Neurobiol. Dis. 573-582
34. Rascol, O., Nutt, J. G., Blin, O., Goetz, C. G., Trugman, J. M., and Soubrouillard, C. 2001, Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease Arch. Neurol. 58, 249-254
35. Delfino, M., Kalisch, R., Czisch, M., Larramendy, C., Ricatti, J., and Taravini, I. R. 2007, Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging Neuropsychopharmacology 32, 1911-1921
36. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat Brain Res. 1158, 135-143
37. 1A receptor stimulation reduced D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat Neuropharmacology 55, 1321-1328
38. Breger, L. S., Dunnett, S. B., and Lane, E. L. (2013) Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat Neurobiol. Dis. 50, 142-150
39. Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., and Weiner, W. J. (2006) Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurol. 66, 983-995
40. You, Z. B., Herrera-Marschitz, M., Nylander, I., Goiny, M., O'Connor, W. T., Ungerstedt, U., and Terenius, L. (1994) The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis: II. Effects of dopamine D1 and D2 receptor agonists Neurosci. 63, 427-434
41. Laprade, N. and Soghomonian, J. J. (1995) Regulation of mRNA levels encoding for two isoforms of glutamate decarboxylase and preproenkephalin in rat striatum by dopaminergic receptors Mol. Brain Res. 34, 65-74
42. Laprade, N. and Soghomonian, J. J. (1997) Glutamate decarboxylase (GAD65) gene expression is increased by dopamine receptor agonists in a subpopulation of rat striatal neurons Mol. Brain Res. 48, 333-345
43. Yamamoto, N. and Soghomonian, J. J. (2008) Timecourse of SKF-81297-induced increase in glutamic acid decarboxylase 65 and 65 mRNA levels in striatonigral neurons and decrease in GABA A receptor α1 subunit mRNA levels in the substantia nigra, pars reticulata, in adult rats with unilateral 6-hydroxydopamine lesion Neuroscience 154, 1088-1099
44. Carta, A. R., Fenu, S., Pala, P., Tronci, E., and Morelli, M. (2003) Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats Eur. J. Neurosci. 18, 2563-2572
45. Antonelli, T., Fuxe, K., Tomasini, M. C., Bartoszyk, G. D., Seyfried, C. A., Tanganelli, S., and Ferraro, L. (2005) Effects of sarizotan on the corticostriatal glutamate pathways Synapse 58, 193-199
46. Mignon, L. J. and Wolf, W. A. (2005) 8-Hydroxy-2-(di-n-propylamino) tetralin reduces striatal glutamate in an animal model of Parkinson's disease NeuroReport 16, 699-703
47. Mengod, G., Vilaro, M. T., Raurich, A., Lopez-Gimenez, J. F., Cortes, R., and Palacios, J. M. (1996) 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors Histochem. J. 28, 747-758
48. Kindlundh-Hogberg, A. M. S., Svenningsson, P., and Schioth, H. B. (2006) Qunatitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain Neuropharmacology 51, 838-847
49. Numan, S., Lundgren, K. H., Wright, D. E., Herman, J. P., and Seroogy, K. B. (1995) Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway Mol. Brain Res. 29, 391-396
50. Frechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., and Luquin, M. 2001, Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys Synapse 39, 288-296
51. 1A) receptors in the MPTP-lesioned macaque Neurobiol. Aging 33 (207) e9-207.e19
52. Huot, P., Johnston, T. H., Visanji, N. P., Darr, T., Pires, D., Hazrati, L., Brotchie, J. M., and Fox, S. H. (2012) Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease Mov. Disord. 27, 735-742
53. Hioki, H., Nakamura, H., Ma, Y. F., Konno, M., Hayakawa, T., Nakamura, K. C., Fujiyama, F., and Kaneko, T. (2010) Vesicular glutamate transporter 3-expressing nonserotonergic projection neurons constitute a subregion in the rat midbrain raphe nuclei J. Comp. Neurol. 518, 668-686
54. 1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors J. Neurochem. 96, 853-860
55. Calabresi, P., Giacomini, P., Centonze, D., and Bernardi, G. (2000) Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity? Ann. Neurol. 47, S60-S68
56. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., and Calabresi, P. (2003) Loss of bidirectional striatal synaptic plasticity in LDOPA-induced dyskinesia Nat. Neurosci. 6, 501-506
57. Yamamoto, N., Pierce, R. C., and Soghomonian, J. J. (2006) Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata Brain Res. 1123, 196-200
58. Rangel-Barajas, C., Silva, I., GarcIa-RamIrez, M., Sanchez-Lemus, E., Floran, L., and Aceves, J. 2008, 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [3H]-GABA release and [3H]-cAMP production in substantia nigra pars reticulata of the rat Neuropharmacology 55, 704-711
59. Kozlowski, M. R. and Marshall, J. F. (1980) Rotation induced by intranigral injections of GABA agonists and antagonists: Zone-specific effects Pharmacol., Biochem. Beh. 561-567
60. Burbaud, P., Bonnet, B., Guehl, D., Lagueny, A., and Bioulac, B. (1998) Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey Brain Res. 780, 102-107
61. Van Wijngaarden, I., Tulp, M., and Soudijn, W. (1990) The concept of selectivity in 5-HT receptor research Eur. J. Pharmacol. 188, 301-312
62. Lorrain, D. S., Matuszewich, L., and Hull, E. M. (1998) 8-OH-DPAT influences extracellular levels of serotonin and dopamine in the medial preoptic area of male rats Brain Res. 790, 217-223
63. Cepeda, C., Hurst, R. S., Altemus, K. L., Flores-Hernandez, J., Calvert, C. R., Jokel, E. S., Grandy, D. K., Low, M. J., Rubinstein, M., Ariano, M. A., and Levine, M. S. (2001) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice J. Neurophysiol. 85, 659-670
64. Monville, C., Torres, E. M., and Dunnett, S. B. (2005) Validation of the L-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists Brain Res. Bull. 68, 16-23
65. Jaunarajs, K. L., Dupre, K. B., Steiniger, A., Klioueva, A., Moore, A., Kelly, C., and Bishop, C. (2009) Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia NeuroReport 20, 1265-1269
66. Muñoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Björklund, A., Bezard, E., and Carta, M. (2009) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain 131, 3380-3394
67. Paxinos, G. and Watson, W. (1998) The Rat Brain in Stereotaxic Coordinates, fourth ed., Academic Press, San Diego.
68. Andersen, P. H. and Jansen, J. A. (1990) Dopamine receptor agonists: Selectivity and dopamine D1 receptor efficacy Eur. J. Pharmacol. 188, 335-347
69. Arnt, J., Hyttel, J., and Sanchez, C. (1992) Partial and full dopamine D1 receptor agonists in mice and rats: Relation between behavioural effects and stimulation of adenylate cyclase activity in vitro Eur. J. Pharmacol. 213, 259-267
70. Adell, A., Carceller, A., and Artigas, F. (1993) In vivo brain dialysis study of the somatodendritic release of serotonin in the Raphe nuclei of the rat: Effects of 8-hydroxy-2-(di- n -propylamino)tetralin J. Neurochem. 60, 1673-1681
71. 1A receptor-induced inhibition of 5-HT neuronal activity in the rat Br. J. Pharmacol. 126, 1741-1750
72. 1A) receptor-mediated attenuation of exercise pressor reflex Brain Res. 900, 186-194
73. Hueston, C. M., Barnum, C. J., Eberle, J. A., Ferraioli, F. J., Buck, H. M., and Deak, T. (2011) Stress-dependent changes in neuroinflammatory markers observed after common laboratory stressors are not seen following acute social defeat of the Sprague Dawley rat Phys. Behav. 104, 187-198